$JBIO
Jade Biosciences, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Waltham, MA
JBIO chart
What traders are saying about $JBIO
Latest postsJade Biosciences, Inc. news
- BTIG reiterates Buy rating on Jade Biosciences, $77 price target
TradingView ·
- Jade Biosciences, Inc. Estimates – NASDAQ:JBIO
TradingView ·
- Jade Biosciences delays Phase 3 trial start for JADE101
Investing.com ·
- Jade Biosciences delays Phase 3 trial start for JADE101 By Investing.com
Investing.com UK ·
- Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026
Yahoo Finance ·
- About 169,000 Americans have IgA kidney disease. Jade expects its trial to start this quarter.
Stock Titan ·
- Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
Yahoo Finance ·
- Jade Biosciences to Participate in Upcoming Conferences
Yahoo Finance ·
- Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?
Yahoo Finance ·
- Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
Yahoo Finance ·
- Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Yahoo Finance ·
- Jade Biosciences Announces Pricing of Public Offering of Common Stock
Yahoo Finance ·
Jade Biosciences, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$127.4M | -$69.6M | -$75.5M | -$51.5M |
| Diluted EPS | $-3.19 | $-2.44 | $-2.87 | $-2.10 |
| Total assets (year end) | $349.8M | $72.8M | $127.4M | $135.3M |
| Cash and equivalents (year end) | $88.4M | $69.4M | $23.5M | $22.4M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Jade Biosciences, Inc.
- Ticker
- JBIO (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Waltham, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1798749
- Former names
- Aerovate Therapeutics, Inc.
Frequently asked questions
What exchange is Jade Biosciences, Inc. listed on?
Jade Biosciences, Inc. trades on the Nasdaq under the ticker symbol JBIO.
What industry is Jade Biosciences, Inc. in?
Jade Biosciences, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Jade Biosciences, Inc. headquartered?
Jade Biosciences, Inc.'s business address on file with the SEC is in Waltham, MA.
When does Jade Biosciences, Inc.'s fiscal year end?
Jade Biosciences, Inc.'s fiscal year ends on December 31.